Genetically based therapeutics for cancer: similarities and contrasts with traditional drug discovery and development.
The field of molecular therapeutics is in its infancy and represents a promising and novel avenue for targeted cancer treatments. Like the small-molecule and antibody therapeutics before them, however, the genetic-based therapies will face significant research and development challenges in their maturation toward an approved cancer therapy. To facilitate this process, we outline and examine in this review the drug development process, briefly summarizing the research and development paradigms that have accompanied the recent successes of the small-molecule and antibody-based cancer therapeutics. Using this background, we compare and contrast the research and development experiences of small-molecule and antibody therapeutics with genetic-based cancer therapeutics, using oncolytic viruses as a defined example of an experimental molecular therapeutic for cancer.
Hermiston
Terry W
TW
Department of Gene Therapy, Berlex Biosciences, Richmond, CA 94941, USA. Terry_hermiston@berlex.com
Kirn
D H
DH
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015195:Drug Design; D015316:Genetic Therapy; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy*; D009841:Oligonucleotides / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use; D014780:Viruses / Q000235:genetics
D000970:Antineoplastic Agents; D009841:Oligonucleotides; D010455:Peptides